| Centra Health - Lynchburg Gen Hospital | |
| 1901 Tate Springs Road, Lynchburg, Virginia 24501 | |
| (434) 200-4789 | |
| Name | Centra Health - Lynchburg Gen Hospital |
|---|---|
| Type | Acute Care Hospital |
| Location | 1901 Tate Springs Road, Lynchburg, Virginia |
| Ownership | Voluntary non-profit - Private |
| Emergency Services | Yes |
| Medicare ID (CCN) | 490021 |
| NPI Number | 1134134869 |
| Organization Name | CENTRAL VIRGINIA HOSPITAL FOR RESTORATIVE AND REHABILITATIVE CARE LLC |
| Doing Business As | CENTRA SPECIALTY HOSPITAL |
| Address | 3300 Rivermont Ave, Lynchburg, VA 24503 |
| Hospital Type | Long Term Care Hospital |
| Phone Number | 434-947-1960 |
News Archive
Researchers have found a crucial enzyme in tuberculosis (TB) to target, allowing the development of new treatments to help fight against the disease's drug resistance.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that it has entered into an exclusive license agreement with the US National Institutes of Health (NIH) for use of adeno-associated virus serotype 5 (AAV5)-based gene therapy vectors for liver and brain indications.
Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, arterial disease and heart failure, today announced its plans to develop vepoloxamer (MST-188) for the treatment of patients with chronic heart failure.
The more enjoyable a physical education program can be made for adolescent girls, the more likely they are to be physically active, according to new research in the March issue of Medicine & Science in Sports & Exercise®, the official journal of the American College of Sports Medicine (ACSM).
› Verified 9 days ago
| NPI Number | 1346428380 |
| Organization Name | CENTRAL VIRGINIA HOSPITAL FOR RESTORATIVE AND REHABILITATIVE CARE, LLC |
| Address | 3300 Rivermont Ave, Lynchburg, VA 24503 |
| Hospital Type | Special Hospital |
| Phone Number | 434-200-1960 |
News Archive
Researchers have found a crucial enzyme in tuberculosis (TB) to target, allowing the development of new treatments to help fight against the disease's drug resistance.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that it has entered into an exclusive license agreement with the US National Institutes of Health (NIH) for use of adeno-associated virus serotype 5 (AAV5)-based gene therapy vectors for liver and brain indications.
Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, arterial disease and heart failure, today announced its plans to develop vepoloxamer (MST-188) for the treatment of patients with chronic heart failure.
The more enjoyable a physical education program can be made for adolescent girls, the more likely they are to be physically active, according to new research in the March issue of Medicine & Science in Sports & Exercise®, the official journal of the American College of Sports Medicine (ACSM).
› Verified 9 days ago
| NPI Number | 1679677983 |
| Organization Name | CENTRA HEALTH INC |
| Doing Business As | LYNCHBURG GENERAL HOSPITAL |
| Address | 1901 Tate Springs Rd, Lynchburg, VA 24501 |
| Hospital Type | General Acute Care Hospital |
| Phone Number | 434-200-3777 |
News Archive
Researchers have found a crucial enzyme in tuberculosis (TB) to target, allowing the development of new treatments to help fight against the disease's drug resistance.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that it has entered into an exclusive license agreement with the US National Institutes of Health (NIH) for use of adeno-associated virus serotype 5 (AAV5)-based gene therapy vectors for liver and brain indications.
Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, arterial disease and heart failure, today announced its plans to develop vepoloxamer (MST-188) for the treatment of patients with chronic heart failure.
The more enjoyable a physical education program can be made for adolescent girls, the more likely they are to be physically active, according to new research in the March issue of Medicine & Science in Sports & Exercise®, the official journal of the American College of Sports Medicine (ACSM).
› Verified 9 days ago
| NPI Number | 1760586077 |
| Organization Name | CENTRA HEALTH INC |
| Doing Business As | VIRGINIA BAPTIST HOSPITAL |
| Address | 3300 Rivermont Ave, Lynchburg, VA 24503 |
| Hospital Type | General Acute Care Hospital |
| Phone Number | 434-947-3777 |
News Archive
Researchers have found a crucial enzyme in tuberculosis (TB) to target, allowing the development of new treatments to help fight against the disease's drug resistance.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that it has entered into an exclusive license agreement with the US National Institutes of Health (NIH) for use of adeno-associated virus serotype 5 (AAV5)-based gene therapy vectors for liver and brain indications.
Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, arterial disease and heart failure, today announced its plans to develop vepoloxamer (MST-188) for the treatment of patients with chronic heart failure.
The more enjoyable a physical education program can be made for adolescent girls, the more likely they are to be physically active, according to new research in the March issue of Medicine & Science in Sports & Exercise®, the official journal of the American College of Sports Medicine (ACSM).
› Verified 9 days ago
| NPI Number | 1770693939 |
| Organization Name | CENTRA HEALTH INC |
| Doing Business As | VIRGINIA BAPTIST LYNCHBURG GEN HOSPITAL |
| Address | 3300 Rivermont Ave, Lynchburg, VA 24503 |
| Hospital Type | General Acute Care Hospital |
| Phone Number | 434-200-3777 |
News Archive
Researchers have found a crucial enzyme in tuberculosis (TB) to target, allowing the development of new treatments to help fight against the disease's drug resistance.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that it has entered into an exclusive license agreement with the US National Institutes of Health (NIH) for use of adeno-associated virus serotype 5 (AAV5)-based gene therapy vectors for liver and brain indications.
Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, arterial disease and heart failure, today announced its plans to develop vepoloxamer (MST-188) for the treatment of patients with chronic heart failure.
The more enjoyable a physical education program can be made for adolescent girls, the more likely they are to be physically active, according to new research in the March issue of Medicine & Science in Sports & Exercise®, the official journal of the American College of Sports Medicine (ACSM).
› Verified 9 days ago
| NPI Number | 1801187547 |
| Organization Name | CENTRA HEALTH, INC |
| Address | 1901 Tate Springs Rd, Lynchburg General Hospital--diabetic-renal Medical Unit, Lynchburg, VA 24501 |
| Hospital Type | General Acute Care Hospital |
| Phone Number | 434-200-3000 |
News Archive
Researchers have found a crucial enzyme in tuberculosis (TB) to target, allowing the development of new treatments to help fight against the disease's drug resistance.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that it has entered into an exclusive license agreement with the US National Institutes of Health (NIH) for use of adeno-associated virus serotype 5 (AAV5)-based gene therapy vectors for liver and brain indications.
Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, arterial disease and heart failure, today announced its plans to develop vepoloxamer (MST-188) for the treatment of patients with chronic heart failure.
The more enjoyable a physical education program can be made for adolescent girls, the more likely they are to be physically active, according to new research in the March issue of Medicine & Science in Sports & Exercise®, the official journal of the American College of Sports Medicine (ACSM).
› Verified 9 days ago
| NPI Number | 1932403813 |
| Organization Name | CENTRA HEALTH, INC. |
| Doing Business As | VIRGINIA BAPTIST HOSPITAL PHARMACY |
| Address | 3300 Rivermont Ave, Lynchburg, VA 24503 |
| Hospital Type | General Acute Care Hospital |
| Phone Number | 434-200-4610 |
News Archive
Researchers have found a crucial enzyme in tuberculosis (TB) to target, allowing the development of new treatments to help fight against the disease's drug resistance.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that it has entered into an exclusive license agreement with the US National Institutes of Health (NIH) for use of adeno-associated virus serotype 5 (AAV5)-based gene therapy vectors for liver and brain indications.
Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, arterial disease and heart failure, today announced its plans to develop vepoloxamer (MST-188) for the treatment of patients with chronic heart failure.
The more enjoyable a physical education program can be made for adolescent girls, the more likely they are to be physically active, according to new research in the March issue of Medicine & Science in Sports & Exercise®, the official journal of the American College of Sports Medicine (ACSM).
› Verified 9 days ago
| Able to receive lab results electronically | Yes |
| Able to track patients' lab results, tests, and referrals electronically between visits | Yes |
News Archive
Researchers have found a crucial enzyme in tuberculosis (TB) to target, allowing the development of new treatments to help fight against the disease's drug resistance.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that it has entered into an exclusive license agreement with the US National Institutes of Health (NIH) for use of adeno-associated virus serotype 5 (AAV5)-based gene therapy vectors for liver and brain indications.
Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, arterial disease and heart failure, today announced its plans to develop vepoloxamer (MST-188) for the treatment of patients with chronic heart failure.
The more enjoyable a physical education program can be made for adolescent girls, the more likely they are to be physically active, according to new research in the March issue of Medicine & Science in Sports & Exercise®, the official journal of the American College of Sports Medicine (ACSM).
› Verified 9 days ago
Centra Health - Lynchburg Gen Hospital Acute Care Hospital Location: 1901 Tate Springs Road, Lynchburg, Virginia 24501 Phone: (434) 200-4789 |